Phase 1 Clinical Studies to begin in First Half of 2020 NEW YORK, January 8, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo Co., Ltd. …
Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn’s and Colitis Foundation’s IBD Innovate Conference
IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system NEW YORK, December 4, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present …
Immunic, Inc. to Participate in Investor and Scientific Conferences in December
NEW YORK, November 25, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management’s participation in the following investor and scientific conferences in December: December 3-5: Piper Jaffray 31st Annual Healthcare Conference: Sanjay Patel, CFA, Chief Financial Officer of Immunic, will present …
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
NEW YORK, November 19, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay “Buck” A. Phillips, an established life sciences executive, investor and entrepreneur, to its Board of Directors, effective November 14, 2019. With this addition, Immunic’s Board will total …
Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
NEW YORK, November 7, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended September 30, 2019 and highlighted recent activity. “The third quarter was marked by several key clinical milestones. Chief among them was the early completion …
Immunic, Inc. to Participate in Industry and Investor Conferences in November
Listen to the Stifel Conference Webcast SAN DIEGO, November 5, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management’s participation in the following industry and investor conferences in November: November 11-13: 25th Annual BIO-Europe International Partnering Conference: Daniel Vitt, Ph.D., Chief Executive Officer and …
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
SAN DIEGO, October 15, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamar Howson, a highly seasoned life sciences executive, to its Board of Directors, effective October 11, 2019. With this addition, Immunic’s Board now totals six members. “Tamar brings …
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
– Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 – SAN DIEGO, October 10, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that the final patient was enrolled and randomized today in the company’s phase 2 EMPhASIS trial …
Immunic, Inc. to Participate in Investor and Scientific Conferences in October
Listen to the Cantor Conference Webcast SAN DIEGO, September 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management’s participation in the following investor and scientific conferences in October: October 2-4: 2019 Cantor Global Healthcare Conference: Daniel Vitt, Ph.D., Chief Executive Officer …
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
SAN DIEGO, September 18, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy volunteer in the company’s phase 1 clinical program of IMU-935, a highly potent and selective inverse agonist of the transcription factor RORγt, believed to be the main …